Prognostic factors for cases with no extracranial metastasis in whom brain metastasis is detected after resection of non-small cell lung cancer

Bae, Min Sun; Yu, Woo Sik; Byun, Go Eun; Lee, Chang Young; Lee, Jin Gu; Kim, Dae Joon; Chung, Kwansoo

doi:10.1016/j.lungcan.2015.02.013

Cited by 18 publications

(17 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: B the Management Of Brain Oligometastasis Of Nsclcmentioning

confidence: 99%

“…In a study by Bae et al, 86 patients had post-operative brain metastasis as the initial recurrence after complete pulmonary resection [34]. The median follow-up time after the initial lung resection was 24.0 months (range: 2-126 months); median overall post-recurrence survival was 11 months [34]. Seventy-nine of the patients (91.9%) were symptomatic at the time of recurrence, 50 patients (58.1%) had multiple metastases, and 62 (72.1%) patients received systemic chemotherapy for brain metastasis [34].…”

Section: B the Management Of Brain Oligometastasis Of Nsclcmentioning

confidence: 99%

“…The median follow-up time after the initial lung resection was 24.0 months (range: 2-126 months); median overall post-recurrence survival was 11 months [34]. Seventy-nine of the patients (91.9%) were symptomatic at the time of recurrence, 50 patients (58.1%) had multiple metastases, and 62 (72.1%) patients received systemic chemotherapy for brain metastasis [34]. Surgical metastasectomy was preformed to 17 of the patients (19.8%); however, the rest of the patients were treated with either SRS or WBRT or combination of treatment modalities [34].…”

Section: B the Management Of Brain Oligometastasis Of Nsclcmentioning

confidence: 99%

“…Surgical metastasectomy was preformed to 17 of the patients (19.8%); however, the rest of the patients were treated with either SRS or WBRT or combination of treatment modalities [34]. An initial lung lesion of adenocarcinoma, non-pneumonectomy patients, a disease-free interval of longer than 10 months from the initial lung resection, solitary brain metastasis, and a size of less than 3 cm for the brain lesion, were reported as positive factors for post-recurrence survive [34].…”

Section: B the Management Of Brain Oligometastasis Of Nsclcmentioning

confidence: 99%

See 3 more Smart Citations

Current surgical management of extrapulmonary oligometastatic non-small cell lung carcinoma

Yazicioğlu¹

2018

Curr Thorac Surg

View full text Add to dashboard Cite

To cite this article: Yazicioglu A. Current surgical management of extrapulmonary oligometastatic non-small cell lung carcinoma. Curr Thorac Surg 2018;3(1):25-37 ABSTRACTLung cancer is one of the leading cause of mortality around the world, and it is widely known that survival is limited in metastatic lung carcinoma cases. However, in oligometastatic, non-small cell lung carcinoma cases, surgical excision of both the primary tumor and the metastatic site may yield a survival advantage in selected cases. In non-small cell lung carcinoma cases, especially after metastasectomy of brain and adrenal gland metastasis, studies in which survival advantage is reported are common in the literature, and metastasectomy is the treatment method applied to selected patient groups in brain and adrenal gland metastases. In surgical treatment of extra-cranial and extra-adrenal oligometastasis, on the other hand, there are several cases in which morbidity-free survival rates were reported after successful management. In this report, the surgical treatment results were evaluated, and the contribution of treatment methods to survival rates were investigated in extrapulmonary oligometastatic non-small cell lung carcinoma cases receiving surgical excision.

show abstract

Section: B the Management Of Brain Oligometastasis Of Nsclcmentioning

confidence: 99%

Section: B the Management Of Brain Oligometastasis Of Nsclcmentioning

confidence: 99%

Section: B the Management Of Brain Oligometastasis Of Nsclcmentioning

confidence: 99%

Section: B the Management Of Brain Oligometastasis Of Nsclcmentioning

confidence: 99%

See 2 more Smart Citations

Current surgical management of extrapulmonary oligometastatic non-small cell lung carcinoma

Yazicioğlu¹

2018

Curr Thorac Surg

View full text Add to dashboard Cite

show abstract

“…In another study (14), the median survival time after diagnosis of synchronous brain metastasis was 12.3 months; 15.4 months for those who received complete surgical resection compared to 11.5 months for those who received whole brain radiotherapy (P=0.002). Bae et al (30) found that adenocarcinoma histology, non-pneumonectomy required for treating the primary tumor, disease free interval longer than 10 months from the lung resection, solitary metastasis and size less than 3 cm are positive factors related to a good post-recurrence survival. Systemic and local treatment of the lesion using surgical resection or stereotactic radiation surgery also improved survival.…”

Section: Brain Metastasismentioning

confidence: 99%

Surgical management of oligometastatic non-small cell lung cancer

2016

View full text Add to dashboard Cite

Survival benefits of primary tumor surgery for synchronous brain metastases: A SEER‐based population study with propensity‐matched comparative analysis

Zhang

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

Background Evidence about the prognostic value of primary tumor surgery (PTS) in patients with brain metastatic malignancies is ambiguous and controversial. This study assessed the survival benefits of primary tumor surgery in patients with brain metastases (BMs). Methods Adults patients with BMs that originated from lung, breast, kidney, skin, colon, and liver diagnosed between 2010 and 2018 were derived from the Surveillance, Epidemiology, and End Results database (SEER). Propensity score matching (PSM) was used to balance the bias between patients with or without PTS. Then the prognostic value of PTS was estimated by Kaplan–Meier analysis and Cox proportional hazard regression models. Results A total of 32,760 patients with BMs secondary to non‐small cell lung cancer (NSCLC), small cell lung cancer (SCLC), breast cancer, renal cancer, melanoma, colorectal cancer, and liver cancer were identified from the database. After PSM at 1:1 ratio, PTS appeared to significantly prolong cause‐specific survival (CSS) time for patients with BMs secondary to NSCLC, breast cancer, renal cancer, and colorectal cancer (hazard ratio [HR] = 0.60 [0.53–0.68], 0.56 [0.43–0.73], 0.47 [0.37–0.60], and 0.59 [0.37–0.95], respectively, all p < 0.05). Patients with earlier T and N classifications, no extracranial metastasis, and cancer‐specific subtypes (adenocarcinoma in NSCLC, hormone receptor‐negative breast cancer) may derive more survival benefits from PTS when suffering from BMs. Conclusion This population‐based study supported PTS could provide survival benefits for patients with BMs secondary to NSCLC, breast cancer, renal cancer, and colorectal cancer. More emphasis should be put on PTS of selected patients with BMs.

show abstract

Prognostic factors for cases with no extracranial metastasis in whom brain metastasis is detected after resection of non-small cell lung cancer

Cited by 18 publications

References 26 publications

Current surgical management of extrapulmonary oligometastatic non-small cell lung carcinoma

Current surgical management of extrapulmonary oligometastatic non-small cell lung carcinoma

Surgical management of oligometastatic non-small cell lung cancer

Survival benefits of primary tumor surgery for synchronous brain metastases: A SEER‐based population study with propensity‐matched comparative analysis

Contact Info

Product

Resources

About